Compare · NTRA vs TRUP
NTRA vs TRUP
Side-by-side comparison of Natera Inc. (NTRA) and Trupanion Inc. (TRUP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and TRUP operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $30.57B, about 31.8x TRUP ($961.8M).
- Over the past year, NTRA is up 30.1% and TRUP is down 56.8% - NTRA leads by 86.9 points.
- NTRA has been more active in the news (16 items in the past 4 weeks vs 14 for TRUP).
- NTRA has more recent analyst coverage (25 ratings vs 12 for TRUP).
- Company
- Natera Inc.
- Trupanion Inc.
- Price
- $213.41-0.88%
- $22.06+0.23%
- Market cap
- $30.57B
- $961.8M
- 1M return
- -2.79%
- -13.66%
- 1Y return
- +30.09%
- -56.78%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 16
- 14
- Recent ratings
- 25
- 12
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Trupanion Inc.
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, Puerto Rico, and Australia. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians. The company was formerly known as Vetinsurance International, Inc. changed its name to Trupanion, Inc. in 2013. Trupanion, Inc. was founded in 2000 and is headquartered in Seattle, Washington.
Latest NTRA
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
Latest TRUP
- Amendment: SEC Form 4 filed by EVP, Trupanion International Wheeler Simon
- Amendment: SEC Form 4 filed by EVP, Trupanion International Wheeler Simon
- Chief Operating Officer Gallagher John R sold $78,153 worth of shares (3,603 units at $21.69) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 33,065 units (SEC Form 4)
- EVP, Trupanion International Wheeler Simon converted options into 2,169 shares and covered exercise/tax liability with 1,017 shares, increasing direct ownership by 5% to 24,239 units (SEC Form 4) (withholding obligation)
- Director Rawlings Darryl converted options into 312 shares, increasing direct ownership by 1% to 24,838 units (SEC Form 4) to cover withholding tax
- CEO Tooth Margaret covered exercise/tax liability with 6,999 shares, sold $10,733 worth of shares (491 units at $21.86) and converted options into 19,042 shares, increasing direct ownership by 7% to 176,379 units (SEC Form 4) to cover withholding tax
- Chief Administration Officer Mcgibney Brenna converted options into 6,431 shares and covered exercise/tax liability with 3,439 shares, increasing direct ownership by 35% to 11,445 units (SEC Form 4) (tax withholding)
- Chief Operating Officer Gallagher John R converted options into 6,793 shares and covered exercise/tax liability with 1,651 shares, increasing direct ownership by 16% to 36,668 units (SEC Form 4) (withholding obligation)
- Director Rubin Howard E converted options into 318 shares, increasing direct ownership by 0.14% to 232,868 units (SEC Form 4)
- Director Powell Bradley S converted options into 639 shares, increasing direct ownership by 50% to 1,906 units (SEC Form 4)